Their mechanistic study suggests that ESR1-e2>CCDC170 fusions bind and stabilize the HER2/HER3/SRC complex and enhance the activation of SRC/PI3K/AKT signaling during ET in vitro and in vivo. The gene discussed is SRC; the disease is essential thrombocythemia.